Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Biopharmaceutical Production and Development Unit (BP&DU)

The Biopharmaceutical Production and Development Unit (BP&DU) supports research-associated topics:

Group 2024 more

Group in 2024

Viral vectors and oncolytic viruses

  • Large Scale production and purification of parvovirus (vector) stocks for pre-clinical applications or basic research
  • Development and optimization of new production, purification and analytic methods with the aim to establish working protocols for GMP-production of virus (vector) stocks necessary for clinical applications and possible market release.
  • Accompanying research in two ParvOryx clinical trials with patient tumor and shedding assessment (see: Research - Treat (
  • In the establishment of GMP-produced parvovirus, the unit plays a pivotal role in the interaction and support of various organizations involved in the approval and application of procedures for virus (vector) production under GMP and GLP-conditions. Cooperation with GMP company (IDT Biologika GmbH) and GLP companies (Biogenes GmbH, Eurofins GmbH, Labor Enders & Kollegen)

Bovine Milk and Meat factors

  • Production and purification of different BMMF´s in prokaryotic and eukaryotic cells.
  • Characterization of BMMF´s regarding quantity, purity, aggregation, stability and activity, isoelectric point (pI), formulation
  • Optimization of the process (upscaling, purity)
  • Optimization of diagnostic assays in different matrices
  • Stability and Stress tests of BMMFs in different formulations


  • Large scale (up to 5 Liter) production and purification of parasites including optimization strategies


  • Large scale (up to 5 Liter) production and purification of pre- GMP- DNA

Assay-Development, Optimization and Qualification

  • Divers immunological, biological and molecular-biological assays (e.g. ELISA, potency, qPCR, endotoxin, stability, deactivation) with standardized SOPs
  • Stability and stress tests for possible drug candidates or antigens for diagnostic
  • Consulting and technical support for production-related inquiries

Focus of the group lies in:

  • Upstream process: establishment, optimization and upscaling of production process
  • Downstream process: optimization of purification process according to impurity profile, quality and quantity
  • Qualified and validated analysis (quantity and quality)
  • Establishment of good process and quality controls
  • Safety assessment (i.e. establishment of optimal deactivation protocols)
  • Consideration of ecological and economical aspects
  • Statistical experiment planning using Design of Experiment approach


Upstream process:

  • Micro- and macrocarrier up to 2.5 Liters for adherent cells
  • Suspension (shaked or stirred) Bacteria and Parasites cultures up to 5 L
  • Production in 10-layer Cell factories (6360 cm², Corning) or fixed bed bioreactor (4 m²) iCellis nano (Pall) For detailed description see Leuchs et al 2016 and Wohlfarth et al 2021


Downstream process:

  • Clarification (centrifugation, filtration with diverse filters up to 0.2µm)
  • Chromatographic purification with ÄKTApure (Cytiva). For H-1PV purification see Leuchs et al 2017
  • Sterile filtration and final formulation

Specific qualitative and quantitative Analysis:

  • Metabolite analysis (Glucose, Lactate, Ammonia, LDH, etc.) with CEDEX Bio analyzer (Roche)
  • Cell and cell cycle characterization with Nucleocounter (Chemometec)
  • Photometric, fluorometric and luminometric analytical methods with FLUOstar Omega (BMG Labtech) for e.g. ELISA, immunoassays, protein-, DNA analysis
  • Characterization of the product using size exclusion chromatography, 2D electrophoresis, protein profile (WB), endotoxin assessment
  • Stability testing as well as establishment of optimal deactivation protocol of H-1PV in regard to regulatory requirements (Frehtman et al; 2023)


to top
powered by webEdition CMS